Pfizer notched another score in the race for an RSV vaccine Tuesday, as it announced the FDA has accepted the Biologics License Application for its maternal RSV vaccine and granted the candidate priority review.
Akebia Therapeutics announced another delay Tuesday in a series of setbacks for vadadustat, being developed to treat anemia linked to chronic kidney disease (CKD).
Actinium Pharmaceuticals’ Iomab-B met the primary endpoint in the Phase III SIERRA trial, demonstrating durable Complete Remission (dCR) at six months in patients with relapsed or refractory acute myeloid leukemia (r/r AML).
Merck & Co. Inc. said on Tuesday its COVID-19 pill was not effective at cutting the risk of coronavirus infections in people living with someone infected with the virus.
Governments should invest in vaccines for all strains of influenza virus that exist in the animal kingdom as an insurance policy in case of an outbreak in humans, the incoming chief scientist at the World Health Organization said on Monday.
Three years later, at least 65 million people worldwide are estimated to have long COVID, according to an evidence review published last month in Nature Reviews Microbiology. More than 200 symptoms have been linked to the syndrome – including extreme fatigue, difficulty thinking, headaches, dizziness when standing, sleep problems, chest pain, blood clots, immune dysregulation, and even diabetes.
Clinical trials for BioNTech’s cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company’s top executive Ugur Sahin told magazine Der Spiegel.
One-year data from a Phase II study of Newron’s schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity.
The U.S. National Institutes of Health (NIH) said on Wednesday that it had started a clinical trial to evaluate Japan’s Shionogi & Co. Ltd.’s experimental oral antiviral drug to treat COVID-19.
Genome engineering company Replay and The University of Texas’ MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.
